<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        6-5223-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DOXORUBICIN 2MG/ML SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOXORUBICIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Intravesical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        175.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01DB01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Doxorubicin is one of a group of medicines called the Anthracycline. These drugs are also known as<br />cancer drugs, chemotherapy, or &quot;chemo&quot;. They are used in the treatment of various cancers to slow or<br />stop the growth of cancer cells. A combination of different types of cancer drugs will often be used to<br />achieve better results and minimize side effects.<br />Doxorubicin concentrate for solution for infusion is used to treat the following forms of cancer:<br />&bull; breast cancer<br />&bull; cancer of the connective tissue, ligaments, bone, muscle (sarcoma)<br />&bull; cancer develops within the stomach or intestine<br />&bull; lung cancer<br />&bull; lymphomas, a cancer affecting the immune system<br />&bull; leukaemia, a cancer that causes abnormal production of blood cell<br />&bull; cancer of the thyroid gland<br />&bull; advance ovarian and endometrial cancer (a cancer of the lining of the uterus or of the uterus)<br />&bull; bladder cancer<br />&bull; advance neuroblastoma (a cancer of the nerve cells commonly found in children)<br />&bull; malignant renal tumour in children (Wilm&acute;s tumour)<br />&bull; myeloma (cancer of the bone marrow)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You must not be given Doxorubicin concentrate for solution for infusion<br />&bull; if you are allergic to Doxorubicin Hydrochloride or any of the other ingredients of this medicine<br />(listed in section 6) or to other Anthracycline<br />&bull; if you have been told your blood is thin (your bone marrow is not working well)<br />&bull; if you have previously been treated with Doxorubicin or similar chemotherapy drugs like, Idarubicin,<br />Epirubicin or Danuorubicin as previous treatment with these similar medicines can increase the risk<br />of side effects with Doxorubicin concentrate for solution for infusion<br />&bull; if you tend to bleed easily<br />&bull; if you suffer from any kind of infection<br />&bull; if you suffer from mouth ulcers<br />&bull; if your liver is not working well<br />&bull; if you suffer from an infection of the bladder (in case the medicine is given to you by an<br />administration in to your bladder)<br />&bull; if there is blood in your urine<br />&bull; if you had a heart attack<br />&bull; if you have impaired heart function, or<br />&bull; if you have serious abnormality of the heart beat (arrhythmia)<br />You should not receive the medicine through a catheter (a thin flexible tube) into your bladder if you<br />have:<br />&bull; a tumour that has grown into the bladder wall<br />&bull; an urinary tract infection<br />&bull; bladder inflammation, or<br />&bull; problems with the insertion of a catheter<br />Warnings and Precautions<br />Talk to your doctor or pharmacist if you have or have had any of the following medical conditions or<br />illnesses:<br />&bull; poor blood cell production in the bone marrow<br />&bull; heart problems<br />&bull; liver disorders, or<br />&bull; kidney disorders<br />You should also tell your doctor:<br />&bull; if you have ever received Doxorubicin or any similar anticancer medicine (Anthracycline) for the<br />treatment of cancer, or<br />&bull; if you have received radiation treatment to the upper body<br />Before starting and during treatment with Doxorubicin concentrate for solution for infusion your doctor<br />will perform the following tests:<br />&bull; blood counts, and<br />&bull; function tests of your heart, liver and kidney<br />Doxorubicin strongly reduces blood cell production in the bone marrow. This may make you more<br />prone to infections or bleeding. It should be made sure that severe infections and/or bleeding can be<br />treated without delay and efficaciously.<br />Tell your doctor immediately:<br />&bull; if you feel a stinging or burning pain at the site of injection. Such a pain can occur if the medicine<br />leaks out of the vein.<br />Your doctor will monitor your heart function carefully during the treatment because:<br />&bull; Doxorubicin may damage the heart muscle.<br />&bull; Doxorubicin treatment may lead to heart failure after a certain cumulative dose (adding up of single<br />doses).<br />&bull; The risk for a heart muscle damage is higher if you have previously received medicines that may<br />damage the heart or radiotherapy of the upper body.<br />The levels of uric acid (showing that cancer cells are destroyed) in your blood may be high during<br />treatment. Your doctor will tell you if you need to take any medicine to control this.<br />&bull; Existing infections should be treated before Doxorubicin concentrate for solution for infusion<br />therapy is started.<br />&bull; This medicinal product is generally not recommended in combination with live, attenuated vaccines.<br />Contact to persons recently vaccinated against polio should be avoided.<br />&bull; As Doxorubicin concentrate for solution for infusion is excreted mainly via the liver and in the bile,<br />its excretion can be reduced if liver function is impaired or the bile ducts narrowed, and this can lead<br />to severe secondary side effects.<br />Doxorubicin concentrate for solution for infusion can turn the urine red. This is not a sign of damage to<br />health.<br />Other medicines and Doxorubicin concentrate for solution for infusion<br />Tell your doctor if you are taking, have recently taken or might take any other medicines.<br />The following medications can interact with Doxorubicin 2mg/ml concentrate for solution for infusion:<br />&bull; Other cytostatics (medication against cancer) e.g. Trastuzumab, Anthracycline (Danuorubicin,<br />Epirubicin, Idarubicin), Cisplatin, Cyclophosphamide, Ciclosporin, Cytarabine, Dacarbazine,<br />Dactinomycin, Fluorouracil, Mitomycin C, Taxanes (e.g. Paclitaxel), Mercaptopurine, Methotrexate,<br />Streptozocin<br />&bull; Cardioactive drugs (medication to treat heart diseases) e.g. Calcium channel blockers, Verapamil,<br />and Digoxin<br />&bull; Medicines that lower the uric acid level in your blood<br />&bull; Inhibitors of Cytochrome P-450 (drugs that stop the substance Cytochrome P-450, which is a<br />important for detoxification of your body, from working: e.g. Cimetidine), drugs inducing<br />Cytochrome P&ndash;450 (e.g. Rifampicin, Barbiturates including Phenobarbital)<br />&bull; Antiepileptic drugs (e.g. Carbamazepine, Phenytoin, Valproate)<br />&bull; Antipsychotics: Clozapine (drug used for schizophrenia)<br />&bull; Heparin (prevents the clotting of blood)<br />&bull; Antiretroviral drugs (medication against special forms of viruses)<br />&bull; Chloramphenicol and Sulphonamides (medication against bacteria)<br />&bull; Progesterone (e.g. at threatening miscarriage)<br />&bull; Amphotericin B (drugs used against fungal diseases)<br />&bull; Live vaccines (e.g. polio (myelitis), malaria)<br />Please note that this can also apply to recently used medicines<br />Pregnancy, Breastfeeding and Fertility<br />Pregnancy<br />It is known that Doxorubicin passes through the placenta and harms the foetus in animal experiments. If<br />you are pregnant, your doctor will give you Doxorubicin only if the benefits of the treatment outweigh<br />the potential harm for the unborn child. Tell your doctor immediately if you are pregnant or think you<br />are pregnant.<br />Breastfeeding<br />Do not breastfeed while you are treated with Doxorubicin concentrate for solution for infusion. The<br />medicine can be passed on to the baby through the breast milk.<br />Fertility<br />If you are a woman, you should not get pregnant during treatment with Doxorubicin or up to 6 months<br />after treatment.<br />If you are a man, you should take adequate precautions to ensure that your partner does not become<br />pregnant during your treatment with Doxorubicin or up to 6 months after treatment and to seek advice<br />on cryoconservation (or cryopreservation) of sperm prior to treatment because of the possibility of<br />irreversible infertility due to therapy with Doxorubicin.<br />If you are considering becoming parents after the treatment, please discuss this with your doctor.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />Due to the frequent occurrence of nausea and vomiting, driving cars and operation of machinery should<br />be discouraged.<br />Doxorubicin concentrate for solution for infusion contains Sodium<br />This medicinal product contains 0.15mmol (3.5mg) sodium per ml. To be taken into consideration by<br />patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Method and routes of administrations<br />Doxorubicin concentrate for solution for infusion can only be given under supervision by a doctor with<br />experience in cancer treatment.<br />Dosage: Your doctor will decide about the dose you will receive.<br />Do not administer the medicine yourself. Your medicine will be given to you as part of an intravenous<br />infusion, into a blood vessel, under the direction of specialists. You will be monitored regularly both<br />during and after your treatment. If you suffer from superficial bladder cancer it is possible that you may<br />receive your medicine into your bladder (intravesical use).<br />Dosage<br />The dosage is usually calculated on the basis of your body surface area. 60-75mg per square metre of<br />body surface area may be given every 3 weeks when used alone. The dosage may need to be reduced to<br />30-60mg per square metre of body surface area and the treatment interval prolonged when given in<br />combination with other antitumour drugs. Your doctor will advise you of how much you will need. If<br />given weekly the recommended dose is 15-20mg per square metre of body surface area. Your doctor<br />will advise you of how much you will need.<br />Patients with reduced liver and renal functions<br />If liver or kidney function is reduced, the dosage should be decreased. Your doctor will advise you of<br />how much you will need.<br />Children, Elderly or Patients after radiotherapy<br />The dosage may need to be reduced in children and the elderly or if you have received any<br />radiotherapy.<br />Your doctor will advise you or how much you need.<br />Patient with bone marrow suppression<br />The dosage may need to be reduced in patient with bone marrow suppression. Your doctor will advise<br />you of how much you need.<br />Obese patients<br />The starting dose may be reduced in obese patients or the dose interval may be prolonged. Your doctor<br />will advise you of how much you need and how often.<br />If you are given more Doxorubicin concentrate for solution for infusion than you should<br />During and after treatment your doctor or nurse will carefully monitor you. The symptoms of an<br />overdose are an extension of Doxorubicin&rsquo;s possible side effects, particularly the blood changes,<br />gastrointestinal and heart problems. Heart disorders may even occur up to six months after you received<br />the over dose.<br />In case of an overdose your doctor will take appropriate measures, such as a blood transfusion and/or<br />treatment with antibiotics.<br />Please tell your doctor if any of the symptoms occur.<br />If you missed a dose of Doxorubicin concentrate for solution for infusion<br />Your doctor will decide on the duration of your treatment with Doxorubicin concentrate for solution for<br />infusion. If the treatment is stopped before the advised courses of treatment is finished, the effects of the<br />Doxorubicin therapy might be reduced. Ask your doctor for advice if you wish to stop the treatment.<br />If you stop using Doxorubicin concentrate for solution for infusion<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Please contact your doctor or nurse immediately if you notice any of the following side effects:<br />&bull; Feeling dizzy, feverish, short of breath with a tight chest or throat or have an itchy rash. This type of<br />allergic reaction can be very serious<br />&bull; Anaemia (a low red blood cell count) that can leave you feeling tired and lethargic<br />&bull; White blood cell counts (Which fight infection) can also drop, increasing the chance of infections<br />and raised temperature (fever)<br />&bull; Platelets (these are cells that help the blood to clot) can be affected which could make you bruise or<br />bleed more easily. It is important to seek medical advice if this happens. Your doctor should test<br />your blood cell count during treatment<br />&bull; Doxorubicin may cause decreased activity in your bone marrow. Your doctor should test your blood<br />cell count during treatment<br />Common (may affect up to 1 in 10 people)<br />&bull; cardiomyopathy (heart muscle disease)<br />&bull; ECG (electrocardiogram) changes<br />&bull; bone-marrow suppression(deficiency in blood cells causing infection and bleeding)<br />&bull; changes to the blood count (leukopenia, neutropenia)<br />&bull; nausea (feeling sick)<br />&bull; vomiting (being sick)<br />&bull; mucositis (inflammation of membranes in digestive tract)<br />&bull; stomatitis (inflammation of membranes in the mouth)<br />&bull; anorexia (eating disorder)<br />&bull; diarrhoea &ndash; may result in dehydration<br />&bull; chemical cystitis (bladder inflammation) sometimes haemorrhagic (with blood in urine) following<br />administration in to the bladder<br />&bull; alopecia (hair loss) normally reversible<br />&bull; sepsis (bacterial infection)<br />&bull; septicaemia (bacterial infection of blood)<br />Uncommon (may affect up to 1 in 100 people)<br />&bull; ulceration and necrosis (death of cell/tissue) of the colon (intestine) in combination with cytarabine<br />phlebitis (inflammation of a vein) gastrointestinal bleeding<br />&bull; abdominal pain<br />&bull; local hypersensitivity reaction of the field of radiation<br />&bull; dehydration<br />Rare (may affect up to 1 in 1,000 people)<br />&bull; secondary acute myeloid leukaemia (blood cancer developed after treatment for another cancer) when<br />in combination with anti-neoplastic drugs which damage the DNA<br />&bull; tumour lysis syndrome (complications of having chemotherapy)<br />&bull; conjunctivitis (inflammation of the outermost layer of the eye)<br />&bull; urticaria (hives)<br />&bull; exanthema (type of rash)<br />&bull; erythematous reactions (rash-like symptoms) along the vein used for the injection<br />&bull; hyperpigmentation (darkened areas) of the skin and nails<br />&bull; onycholysis (loosening of the nails)<br />&bull; anaphylactic reaction (severe allergic reactions with or without shock including skin rash, pruritis<br />(itching)<br />&bull; shivering<br />&bull; fever<br />&bull; dizziness<br />Not known (frequency cannot be estimated from the available data)<br />&bull; acute lymphocytic leukaemia (disease in which too many immature white blood cells called<br />lymphoblasts are found in the blood and bone marrow)<br />&bull; acute myelogenous leukaemia (disease in which too many immature blood-forming cells are found in<br />the blood and bone marrow)<br />&bull; thrombophlebitis (vein inflammation under the skin)<br />&bull; thromoembolism (clot formed in a blood vessel)<br />&bull; decreased amounts of a blood clotting factor (thrombocytes)<br />&bull; shock<br />&bull; chills<br />&bull; inflammation of food pipe (oesophagitis)<br />&bull; inflammation of the large intestine (colitis)<br />&bull; arrhythmia (irregular heartbeat)<br />&bull; heart failure (loss of cardiac function)<br />&bull; hyperuricaemia (high uric acid level in blood)<br />&bull; bronchospasm (coughing or difficulty in breathing because of narrowing sudden of airways)<br />&bull; pneumonitis (inflammation of lung tissue)<br />&bull; amenorrhoea (absence of menstruation)<br />&bull; oligospermia (low sperm volume)<br />&bull; acute renal (kidney) failure (low urine output/or no urine)keratitis (inflammation of the cornea of the<br />eye)<br />&bull; lacrimation (excessive secretion of tears)<br />&bull; acral erythema (swelling and numbness of the hands and feet)<br />&bull; plantar-palmar dysaesthesia (hand-to-foot syndrome is a distinctive and relatively frequent skin toxic<br />reaction)<br />&bull; excessive pigmentation of oral mucosa<br />&bull; feeling of intense heat (hot flushes)<br />&bull; azoospermia (lack of sperml<br />&bull; anaemia (reduction of red blood cells)<br />&bull; a stinging or burning sensation at the administration site in relation to extravasation. Extravasation<br />can lead to local death of calls of the tissue which may require surgical measures<br />&bull; liver toxicity<br />&bull; transient increase of liver enzymes<br />&bull; asthenia (loss or lack of bodily strength; weakness; debility)<br />&bull; photosensitivity (increased sensitivity of the skin to sun)<br />Other Side effects: Doxorubicin concentrate for solution for infusion may cause a red colouration of<br />the urine for one or two days after administration. This is normal and nothing to worry about.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side<br />effects not listed in this. You can also report the side effects directly to the National Pharmacovigilance<br />Centre (NPC) (See Section 6). By reporting side effects, you can help provide more information on the<br />safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.<br />Store in a refrigerator (2&deg;C - 8&deg;C). Keep the vial in the outer pack in order to protect from light. Do not<br />use this medicine after the expiry date which is stated on the pack. The expiry date refers to the last day<br />of that month.<br />Do not use this medicine if you notice that it is not a clear red coloured particle-free solution.<br />For single use only.<br />Any unused product or waste material should be disposed of in accordance with local requirements.<br />Observe guidelines for handling cytotoxic drugs.<br />Prepared infusion solutions: Chemical and physical in-use stability has been demonstrated in 0.9%<br />sodium chloride injection and 5% dextrose injection for up to 28 days at<br />2&deg;C&ndash; 8&deg;C and for up to 7 days at 25&deg;C when prepared in glass containers protected from light.<br />From a microbiological point of view, the product should be used immediately. If not used immediately,<br />in-use storage times and conditions prior to use are the responsibility of the user and would normally<br />not be longer than 24 hours at 2&deg;C to 8&deg;C, unless dilution has taken place in controlled and validated<br />aseptic condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Doxorubicin concentrate for solution for infusion contains the active ingredient Doxorubicin<br />Hydrochloride.<br />Each ml contains 2mg Doxorubicin Hydrochloride<br />Each 5ml vial contains 10mg of Doxorubicin Hydrochloride.<br />Each 10ml vial contains 20mg of Doxorubicin Hydrochloride.<br />Each 25ml vial contains 50mg of Doxorubicin Hydrochloride.<br />Each 50ml vial contains 100mg of Doxorubicin Hydrochloride.<br />Each 100ml vial contains 200mg of Doxorubicin Hydrochloride.<br />The other ingredients are sodium chloride, hydrochloric acid (for pH adjustment) and water for<br />injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Doxorubicin concentrate for solution for infusion is a clear, red solution, which is practically free from
particles.
Pack sizes:
1 x 5ml vial (10mg/5ml)
1 x 10ml vial (20mg/10ml)
1 x 25ml vial (50mg/25ml)
1 x 50ml vial (100mg/50ml)
1 x 100ml vial (200mg/100ml)
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow,<br />Middlesex HA1 4HF, United Kingdom.<br />Manufactured for Accord Healthcare Limited by:<br />Intas Pharmaceuticals Limited, Ahmedabad, Gujarat state, India.<br />For any information about this medicinal product, please contact the local representative of the<br />MAH:<br />Accord Healthcare KSA Scientific Office<br />At Zimmo Trading Company Ltd.<br />Riyadh, Olaya, Al-Arfaj Street, branched from Abdulmalik Bin Marwan Street,<br />Behind Ministry of Interior, Atlas building, office No. 1<br />Tel: +966-11-217-0140<br />E-mail: mena-pv@accord-healthcare.com<br />This leaflet was last approved in 03/2020, version number SA-02.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance Centre (NPC):<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />&bull; SFDA Call Centre: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 03/2020, version number SA-02.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>دوكسوروبیسین ھو واحد من مجموعة الأدویة التي تُسمى الأنثراسیكلینات. كما تُعرف ھذه الأدویة أیضًا بالأدویة المضادة للسرطان<br />أو أدویة العلاج الكیمیائي أو &quot;الكیمو&quot;. وھي أدویة تُستخدم لعلاج مختلف أنواع السرطانات لتقلیل أو وقف نمو الخلایا السرطانیة.<br />وعادة ما یتم استخدام مجموعة من الأدویة المختلفة المضادة للسرطان لتحقیق نتائج أفضل وتقلیل التأثیرات الجانبیة.<br />یُستَخدَم دوكسوروبیسین محلول مُركز للتسریب الوَریدي لعلاج انواع السرطانات التالیة:<br />&bull; سرطان الثدي<br />&bull; سرطان الأنسجة الضامة، سرطان الأربطة، سرطان العظام، سرطان العضلات (الساركوما &quot;وھو مصطلح عام لمجموعة مختلفة<br />من السرطانات التي تُصیب العظام والأنسجة الرِّخوة&quot;)<br />&bull; تفاقم سرطان المعدة أو الأمعاء الدقیقة<br />&bull; سرطان الرئة<br />&bull; سرطان الغدد اللمفاویة، وھو سرطان یؤثر على الجھاز المناعي<br />&bull; سرطان الدم (اللوكیمیا)، وھو سرطان یؤدي إلى انتاج خلایا الدم بشكلِ غیر طبیعي<br />&bull; سرطان الغدة الدرقیة<br />&bull; سرطان المبیض وبطانة الرحم في المراحل المتقدمة (وھو سرطان یصیب الرحم أو بطانة الرحم)<br />&bull; سرطان المثانة<br />&bull; سرطان الخلایا البدائیة العصبیة (نیوروبلاستوما) في المراحل المتقدمة (وھو سرطان یُصیب الخلایا العصبیة ویكون أكثر شیوعًا<br />في الأطفال)<br />&bull; ورم كلوي خبیث (ورم ویلمز) یُصیب الأطفال<br />&bull; المایلوما (ورمٌ نقويٌ) (وھو سرطان یصیب النخاع العظمي)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحظر إعطائك دوكسوروبیسین محلول مُركز للتسریب الوَریدي في الحالات التالیة:<br />&bull; إذا كنت تعاني من حساسیة تجاه دوكسوروبیسین ھیدروكلورید أو تجاه أي مكون من المكونات الأخرى الداخلة في تركیب ھذا<br />الدَّواء (المدرجة في القسم رقم ٦) أو تجاه الأدویة الأخرى من مجموعة الأنثراسیكلینات<br />&bull; إذا اُخبرت أنك تعاني من سیولة في الدم (لا یعمل نخاع العظام لدیك بشكلِ سلیم)<br />&bull; إذا تم علاجك مُسبقًا باستخدام دوكسوروبیسین أو أي أدویة كیمیائیة مشابھة مثل ایداروبوسین أو ایبیروبوسین أو داونوروبیسین،<br />حیث أن العلاج السابق باستخدام ھذه الأدویة قد یزید من مخاطر التعرض للتأثیرات الجانبیة لدواء دوكسوروبیسین محلول مُركز<br />للتسریب الوَریدي<br />&bull; إذا كنت تُعاني من احتمالیة النزیف بسھولة<br />&bull; إذا كنت تُعاني من أي عدوى<br />&bull; إذا كنت تُعاني من قرح بالفم<br />&bull; إذا كنت تعاني من قصور في وظائف الكبد<br />&bull; إذا كنت تعاني من التھاب المثانة (في حالة تم إعطائك الدواء داخل المثانة)<br />&bull; إذا كنت تعاني من وجود دم في البول<br />&bull; إذا عانیت مُسبقًا من أزمة قلبیة<br />&bull; إذا كنت تعاني من قصور في وظائف القلب<br />&bull; إذا كنت تعاني من عدم انتظام ضربات القلب (اضطراب نظم القلب)<br />یحظر إعطائك الدواء باستخدام القسطرة (أنبوبة رفیعة مرنة) داخل المثانة، إذا كنت تعاني من<br />&bull; بدایة ظھور ورم في جدار المثانة<br />&bull; عدوى في المسالك البولیة<br />&bull; التھاب المثانة<br />&bull; حدوث اضطرابات عند إدخال القسطرة<br />تحذیرات واحتیاطات<br />یُرجى إبلاغ طبیبك المعالج أو الصیدلي إذا كنت تعاني أو قد عانیت في السابق من أيِ من الحالات الطبیة أو الأمراض التالیة:<br />&bull; قلة إنتاج خلایا الدَّم في النخاع العظمي<br />&bull; مشاكل بالقلب<br />&bull; اضطرابات بالكبد<br />&bull; اضطرابات بالكُلى<br />كما ینبغي علیك أیضًا إبلاغ طبیبك المعالج في الحالات التالیة:<br />&bull; إذا تم إعطائك دوكسوروبیسین أو أي أدویة مضادة للسرطان مماثلة للأنثراسیكلینات المُستخدمة لعلاج السرطانات<br />&bull; إذا كنت تخضع للعلاج الإشعاعي على الجزء العلوي من الجسم<br />قبل البدء وأثناء العلاج باستخدام دوكسوروبیسین محلول مُركز للتسریب الوَریدي، سیقوم طبیبك المعالج بإجراء الفحوصات التالیة:<br />&bull; فحص عدد خلایا الدم الكاملة<br />&bull; فحص وظائف القلب والكبد والكلى<br />یقلل دوكسوروبیسین إنتاج خلایا الدم بشدة في النخاع العظمي. وقد یجعلك ذلك أكثر عُرضة للإصابة بالعدوى أو النزیف. یُرجى<br />التأكد من أنھ یمكن علاج كلٍ من حالات العدوى و/أو النزیف الشدیدة بشكلِ سریع وفعّال.<br />أخبر طبیبك المعالج فورًا إذا عانیت من أيِ من الحالات الآتیة:<br />&bull; إذا شعرت بوخز أو ألم شدید في موضع الحقن. فقد یكون ھذا الألم ناجمًا عن تسرب الدواء خارج الورید<br />سوف یقوم طبیبك المعالج بمتابعة وظائف القلب بعنایة أثناء تلقي العلاج للأسباب التالیة:<br />&bull; قد یؤدي دوكسوروبیسین إلى ضمور عضلة القلب<br />&bull; قد یؤدي العلاج باستخدام دوكسوروبیسین إلى قصور القلب عقب تلقي جرعة تراكمیة محددة (إضافة الجرعات الفردیة في شكل<br />جرعة واحدة)<br />&bull; تزداد مخاطر ضمور عضلة القلب، إذا تم إعطائك مسبقًا أدویة قد تؤدي إلى اتلاف القلب أو إذا كنت خضعت للعلاج الاشعاعي<br />على الجزء العلوي من الجسم<br />قد ترتفع مستویات حمض الیوریك في الدم (یرجع ذلك إلى موت الخلایا السرطانیة). سیخبرك طبیبك المعالج ما إذا كنت بحاجة إلى<br />تناول أي أدویة أخرى لعلاج ذلك.<br />&bull; ینبغي معالجة أي عدوى مُصاب بھا قبل البدء في العلاج باستخدام دوكسوروبیسین محلول مُركز للتسریب الوَریدي.<br />&bull; لا یُوصى باستخدام ھذا الدواء بشكلِ عام بالتزامن مع تلقي اللَّقاحات الحیة أو الضعیفة (الموَھَّنة). ینبغي تجنب التعامل مع<br />الأشخاص الذین تلقوا لقاح ضد شلل الأطفال مؤخرًا.<br />&bull; بما أنھ یتم إخراج دوكسوروبیسین محلول مُركز للتسریب الوَریدي عن طریق الكبد والمرارة بشكلِ أساسي، فقد یصبح معدل<br />إخراجھ بطیئًا عند وجود قصور في وظائف الكبد أو ضیق في القنوات المراریة، والذي بدوره قد یؤدي إلى ظھور تأثیرات جانبیة<br />ثانویة خطیرة.<br />قد یتسبب دوكسوروبیسین محلول مُركز للتسریب الوَریدي في تغیر لون البول إلى اللون الأحمر. ومع ذلك، لا یعد ذلك علامة على<br />تدھور حالتك الصحیة.<br />استخدام دوكسوروبیسین محلول مُركز للتسریب الوَریدي مع الأدویة الأخرى<br />أخبر طبیبك المُعالج، إذا كنت تتناول أو قد تناولت مؤخرًا أو قد تتناول أیة أدویة أخرى.<br />قد تتفاعل الأدویة التالیة مع دوكسوروبیسین ۲ ملغم/مللیلتر محلول مُركز للتسریب الوَریدي:<br />&bull; أدویة مثبطة لنمو الخلایا السرطانیة (أدویة تستخدم لعلاج السرطان) مثل، تراستوزوماب، أنثراسیكلین (مثل داونوروبیسین،<br />إیبیروبیسین، إیداروبیسین)، سیسبلاتین، سیكلوفوسفامید، سیكلوسبورین، سیتارابین، داكاربازین، داكتینومایسین، فلورویوراسیل،<br />میتومیسین سي، التاكسنات (مثل باكلیتاكسیل)، مركابتوبورین، میثوتریكسیت، ستربتوزوسین.<br />&bull; الأدویة الفعالة في اضطرابات القلب (أدویة تستخدم لعلاج أمراض القلب) مثل: مُحْصِراتُ قنوات الكالسیوم وفیرابامیل<br />ودیجوكسین.<br />&bull; الأدویة التي تستخدم لتقلیل مستویات حمض الیوریك في الدم.<br />&bull; مثبطات انزیم سیتوكروم ب ي ٤٥۰ (أدویة تستخدم لوقف انزیم سیتوكروم بي ٤٥۰ ، وھي مواد ھامة لإزالة المواد السامة من<br />الجسم وتثبیط نشاطھا: مثل، سیمیتیدین)، وأدویة محفزة لإنزیم سیتوكروم بي ٤٥۰ (مثل ریفامبیسین، باربیتورات بما في ذلك<br />فینوباربیتال)<br />&bull; الأدویة التي تستخدم لعلاج مرض الصرع (مثل: كَرْبامازِیبین، فینیتوین، فالبروات)<br />&bull; أدویة مضادة للذھان: كلوزابین (دواء یُستخدم لعلاج حالات انفصام الشخصیة)<br />&bull; ھیبارین (دواء یُستخدم لمنع تجلط الدم)<br />&bull; الأدویة التي تستخدم لعلاج فیروسات النسخ العكسي (أدویة تُستخدم لعلاج أنواع محددة من الفیروسات)<br />&bull; كلورامفینیكول وسالفونامیدات (أدویة مضادة للجراثیم والبكتیریا)<br />&bull; بروجستیرون (على سبیل المثال لعلاج حالات الحمل المھددة بالإجھاض)<br />&bull; أمفوتریسین &quot;ب&quot; (أدویة تُستخدم لعلاج عدوى الفطریات)<br />&bull; اللقاحات الحیة:(مثل: لقاح شلل الأطفال (التھاب النخاع الشوكي)، الملاریا)<br />یُرجى ملاحظة أن ھذه المعلومات قد تنطبق أیضًا على الأدویة التي تم استخدامھا مؤخرًا.<br />الحمل والرَّضاعة الطبیعیة والخصوبة<br />الحمل<br />أظھرت نتائج التجارب التي تم اجراءاھا على الحیوانات أن دوكسوروبیسین ینتقل عبر المشیمة ویسبب تشوھات للجنین. إذا كنتِ<br />حاملًا، فسیقرر طبیبكِ المعالج إعطائكِ دوكسوروبیسین فقط إذا كانت فوائد العلاج تفوق أضراره المحتملة على الجنین. إذا كنتِ<br />حاملًا أو تعتقدین أنكِ قد تكونین حاملًا، یُرجى إبلاغ طبیبكِ المعالج فورًا.<br />الرضاعة الطبیعیة<br />یحظر علیكِ الرضاعة الطبیعیة أثناء فترة العلاج باستخدام دوكسوروبیسین محلول مُركز للتسریب الوَریدي. فقد یفرز ھذا الدواء في<br />حلیب الأم ویصل إلى الطفل.<br />الخصوبة<br />یحظر على السیدات التخطیط للحمل أثناء فترة العلاج بدوكسوروبیسین أو خلال ٦ أشھر عقب تلقي أخر جرعة علاجیة.<br />ینبغي على الرجال اتباع الاحتیاطات الكافیة لضمان عدم حدوث حمل لزوجتھ أثناء فترة تلقي العلاج بدواء دوكسوروبیسین ولمدة<br />تصل إلى ٦ أشھر عقب تلقي أخر جرعة علاجیة، وینبغي أیضًا طلب النصیحة بشأن عملیة تجمید الحیوانات المنویة (حفظھا<br />بالبرودة) قبل بدأ العلاج باستخدام دوكسوروبیسین لأنھ قد یؤدي إلى الإصابة بالعقم الدائم.<br />إذا رغبا الزوجان في الانجاب عقب العلاج، یُرجى استشارة الطبیب المعالج.<br />استشر طبیبك المعالج أو الصیدلي للحصول على النصیحة قبل تناول أي دواء.<br />القیادة واستخدام الآلات<br />لا یوصى بقیادة سیارات وتشغیل الآلات نظرًا إلى كثرة التعرض لغثیان وقيء.<br />یحتوي دوكسوروبیسین محلول مُركز للتسریب الوَریدي على الصودیوم<br />یحتوي ھذا الدواء على ۰٫۱٥ مللي مول ( ۳٫٥ ملغم) من الصودیوم لكل مل. ویجب أخذ ھذه المعلومة بعین الاعتبار مع المرضى<br />الذین یتبعون نظامًا غذائیًا مُضبوطًا بنسبة الصودیوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>طرق وأسالیب إعطاء الدواء<br />لا ینبغي إعطاء دوكسوروبیسین محلول مُركز للتسریب الوَریدي إلا تحت إشراف طبیب ذو خبرة في علاج السرطانات.<br />مقدار الجرعة: سیحدد طبیبك المعالج مقدار الجرعة التي یجب أن تتلقاھا.<br />لا تقم بإعطاء الدواء لنفسك. سوف یتم إعطائك الدواء عن طریق الحقن بالتسریب داخل الورید في الأوعیة الدمویة تحت إشراف<br />أخصائیین. سوف یتم متابعتك بصورة مستمرة أثناء وعقب العلاج. إذا كنت تعاني من سرطان المثانة السطحي، فمن المحتمل أن یتم<br />إعطائك الدواء داخل المثانة (الحقن داخل المثانة).<br />الجرعة<br />عادة ما یتم تحدید مقدار الجرعة على أساس مساحة سطح الجسم. یمكن إعطاء جرعة یتراوح مقدارھا من ٦۰ إلى ۷٥ ملغم / م ۲ من<br />مساحة سطح الجسم كل ۳ أسابیع عند استخدام ھذا الدواء بمفرده. فقد تحتاج إلى تقلیل الجرعة لتصل إلى ۳۰ إلى ٦۰ ملغم/م ۲ من<br />مساحة سطح الجسم، وقد تطول الفترة الفاصلة بین جرعات الدواء عند أخذه متزامنًا مع غیره من الأدویة المضادة للأورام. سیقوم<br />طبیبك المعالج بتحدید مقدار الجرعة المناسبة لك. إذا تم إعطاء ھذا الدواء أسبوعیًا تكون الجرعة المُوصى بھا ھي ۱٥ إلى<br />۲۰ ملغم/ م ۲ من مساحة سطح الجسم. سیقوم طبیبك المعالج بتحدید مقدار الجرعة المناسبة لك.<br />الاستخدام في المرضى الذین یعانون من قصور في وظائف الكبد والكلى<br />ینبغي تقلیل الجرعة، إذا حدث انخفاض في وظائف الكبد أو الكلى. سیقوم طبیبك المعالج بتحدید مقدار الجرعة المناسبة لك.<br />الاستخدام في المرضى من الأطفال، كبار السن أو في المرضى عقب تلقیھم العلاج الإشعاعي<br />قد یكون تقلیل الجرعة أمرًا ضروریًا في المرضى من الأطفال وكبار السن أو الذین قد تلقوا علاجًا إشعاعیًا. سیقوم طبیبك المعالج<br />بتقدیم المشورة بشأن تحدید مقدار الجرعة المناسبة لك.<br />الاستخدام في المرضى الذین یعانون من تثبیط النخاع العظمي<br />قد یكون تقلیل الجرعة أمرًا ضروریًا في المرضى الذین یعانون من تثبیط النخاع العظمي. سیقوم طبیبك المعالج بتقدیم المشورة بشأن<br />تحدید مقدار الجرعة المناسبة لك.<br />الاستخدام في المرضى الذین یعانون من السمنة<br />قد یتم تقلیل جرعة البدء في المرضى الذین یعانون من السمنة أو إطالة الفترة الفاصلة بین الجرعات. سیقوم طبیبك المعالج بتقدیم<br />المشورة بشأن تحدید مقدار الجرعة المناسبة لك وعدد مراتھا.<br />إذا تم إعطائك أكثر مما یجب من دوكسوروبیسین محلول مُركز للتسریب الوَریدي<br />سیقوم طبیبك المعالج أو الممرض بمتابعتك بعنایة أثناء وعقب العلاج. تشتمل أعراض أخذ جرعة زائدة على إطالة فترة الإصابة<br />بالتأثیرات الجانبیة المحتملة لدواء دوكسوروبیسین. وخاصًة تغییرات الدم، واضطرابات الجھاز الھضمي والقلب. قد تحدث<br />اضطرابات القلب حتى ستة أشھر عقب تلقي الجرعة الزائدة.<br />في حالة إعطائك جرعة زائدة، فسیقوم طبیبك المعالج بأخذ التدابیر المناسبة. مثل نقل الدم و/أو العلاج بالمضادات الحیویة.<br />أخبر طبیبك المعالج إذا تعرضت لأیة تأثیرات جانبیة.<br />إذا أغفلت أخذ جرعة من دوكسوروبیسین محلول مُركز للتسریب الوَریدي<br />سیقوم طبیبك المعالج بتحدید مدة العلاج بدواء دوكسوروبیسین محلول مُركز للتسریب الوَریدي. إذا تم إیقاف العلاج قبل استكمال<br />الدورات العلاجیة الموصي بھا، فمن المحتمل أن تقل فعّالیة دوكسوروبیسین. استشر طبیبك المعالج للحصول على النصیحة، إذا<br />رغبت في إیقاف العلاج.<br />إذا توقفت عن استخدام دوكسوروبیسین محلول مُركز للتسریب الوَریدي<br />إذا كانت لدیك أیة أسئلة إضافیة حول استخدام ھذا الدواء، فاستشر طبیبك المعالج أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>یمكن أن یُسبب ھذا الدَّواء، مثلھ مثل كافة الأدویة، تأثیرات جانبیة على الرغم من عدم حدوثھا لجمیع المرضى.<br />ا من التأثیرات الجانبیة التالیة: 􀌒 أخبر طبیبك المعالج أو الممرض فورًا إذا لاحظت أی<br />&bull; شعور بدوخة، حمى، ضیق بالتنفس یصاحبھ ضیق في الصدر أو الحلق أو طفح جلدي. وقد یكون ھذا النوع من تفاعلات<br />الحساسیة خطیر جدًا.<br />&bull; أنیمیا &quot;فقر الدم&quot; (وھو انخفاض عدد خلایا الدم الحمراء)، مما یتسبب في الشعور بالتعب والخمول.<br />&bull; قد ینخفض أیضًا عدد خلایا الدم البیضاء (وھي المسئولة عن مقاومة العدوى)، مما یزید من احتمالیة الاصابة بعدوى وارتفاع<br />درجة الحرارة (حمى).<br />&bull; قد تتأثر الصفائح الدَّمویة (وھي خلایا تساعد على تجلط الدم)، مما یجعلك أكثر عرضة للإصابة بكدمات أو النزیف بسھولة. من<br />الضروري طلب النصیحة الطبیة إذا تعرضت لذلك. ینبغي على طبیبك المعالج طلب فحص عدد خلایا الدم أثناء فترة العلاج.<br />&bull; قد یتسبب دوكسوروبیسین في تقلیل نشاط النخاع العظمي. ینبغي على طبیبك المعالج طلب فحص عدد خلایا الدم أثناء فترة<br />العلاج.<br />تأثیرات جانبیة شائعة (قد تؤثر على ما یصل إلى مریض واحد من بین كل ۱۰ مرضى)<br />&bull; اعتلال عضلة القلب (ضعف بعضلة القلب)<br />(ECG) &bull; تغییرات في مخطط كھربائیة القلب<br />&bull; تثبیط النخاع العظمي (نقص في عدد الخلایا فیؤدى إلى الإصابة بالعدوى والنزیف)<br />&bull; تغییرات في عدد خلایا الدم (قلة كریات الدم البیضاء، قلة خلایا العدلات)<br />&bull; غثیان (شعور بإعیاء)<br />&bull; قيء (إعیاء)<br />&bull; التھاب الغشاء المخاطي (التھاب الأغشیة المخاطیة في الجھاز الھضمي)<br />&bull; التھاب الفم (التھاب الأغشیة المخاطیة في الفم)<br />&bull; فقدان الشھیة (اضطرابات في الأكل)<br />&bull; إِسْھال، قد یتسبب في حدوث جفاف<br />&bull; التھاب المثانة الكیمیائي (التھاب المثانة) وأحیانًا الاصابة بنزیف (مصحوبًا بوجود دم مع البول) عقب إعطاء الدواء داخل المثانة<br />&bull; ثعلبة (تساقط الشعر) ویمكن علاجھ عادًة<br />&bull; تعفن الدم (عدوى بكتیریة)<br />&bull; تسمم الدم (عدوى بكتیریة في الدم)<br />تأثیرات جانبیة غیر شائعة (قد تؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰ مرضى)<br />&bull; تقرحات وموت مبكر لخلایا الجسم &quot;نخر&quot; (موت الخلایا/الأنسجة) في القولون (الأمعاء الدقیقة) عند استخدام دواء سیتارابین<br />لعلاج الالتھابات الوریدیة (التھاب الورید)، نزیف بالجھاز الھضمي<br />&bull; آلام بالبطن<br />&bull; تفاعلات فرط الحساسیة الموضعیة الناجمة عن تلقي العلاج الاشعاعي<br />&bull; جفاف<br />تأثیرات جانبیة نادرة (قد تؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰۰ مریض)<br />&bull; سرطان الدم النخاعي الثانوي الحاد (اللوكیمیا) (ظھور سرطان الدم عقب تلقي علاج لنوع أخر من السرطانات) عند أخذه<br />(DNA بالتزامن مع أدویة أخرى مضادة للأورام تعمل عن طریق إتلاف خلایا الحمض النووي<br />&bull; متلازمة انحلال الورم (مضاعفات تحدث عقب تلقي العلاج الكیمیائي)<br />&bull; التھاب الملتحمة (التھاب الطبقة الخارجیة للعین)<br />&bull; أرتكاریا (شرى)<br />&bull; طفح ظاھر (نوع من أنواع الطفح الجلدي)<br />&bull; تفاعلات حمامیة (أعراض تشبھھ الطفح) تظھر على امتداد الورید في موضع الحقن<br />&bull; تغیرات بلون (تغیر لون مناطق بالبشرة إلى لون أغمق) البشرة والأظافر<br />&bull; اقتلاع الأظافر (سقوط الأظافر)<br />&bull; تفاعل تَأَقِيّ (تفاعلات حساسیة شدیدة مع أو بدون صدمة تشتمل على طفح جلدي، حكة في الجلد)<br />&bull; رعشة<br />&bull; حُمى<br />&bull; دوخة<br />تأثیرات جانبیة غیر معروف معدّل تكرارھا (لا یمكن تقدیر معدل التكرار من واقع البیانات المتاحة)<br />&bull; سرطان الدم اللیمفاوي الحادّ (وھو مرض یحدث بسبب إنتاج عدد كبیر من خلایا الدم البیضاء غیر مكتملة النمو والتي تُعرف<br />بالخلایا الأرومة اللمفاویة في الدم ونخاع العظم)<br />&bull; سرطان الدم النِقَوِيُّ الحادّ (وھو مرض یحدث بسبب إنتاج عدد كبیر من خلایا الدم البیضاء غیر مكتملة النمو في الدم ونخاع<br />العظم)<br />&bull; التھاب الورید الخثاري (التھاب الورید تحت سطح الجلد)<br />&bull; جلطات دمویة (وھو عبارة عن جلطات دمویة تتكون في الأوعیة الدمویة)<br />&bull; نقص في عدد العوامل المسؤولة عن تجلط الدم (الصفیحات الدمویة)<br />&bull; صدمة<br />&bull; قشعریرة<br />&bull; التھاب موضع أنبوب التغذیة (التھاب المريء)<br />&bull; التھاب الأمعاء الغلیظة (التھاب القولون)<br />&bull; اضطراب نظم القلب (عدم انتظام ضربات القلب)<br />&bull; فشل القلب (قصور في وظائف القلب)<br />&bull; فرط حمض یوریك الدم (ارتفاع مستویات حمض الیوریك في الدم)<br />&bull; تشنج قصبي (سعال أو صعوبة في التنفس بسبب ضیق مفاجئ في الشعب الھوائیة)<br />&bull; التھاب رئوي (التھاب نسیج الرئة)<br />&bull; انقطاع الحیض (توقف الدورة الشھریة الحیض)<br />&bull; قلة الحیوانات المنویة (نقص عدد الحیوانات المنویة)<br />&bull; فشل كلوي حاد (نقص في معدل إخراج البول/أو عدم وجود بول) التھاب القرنیة (التھاب قرنیة العین)<br />&bull; كثرة إفراز الدموع (فرط افراز الدموع)<br />&bull; ظھور أشكال حمامي على الأطراف (تورم وتنمیل في الیدین والقدمین)<br />&bull; تنمیل بالسطح الراحي الأخمصي (&quot;متلازمة الید والقدم وھي تفاعلات جلدیة سامة ومتكررة نسبیًا)<br />&bull; فرط تصبغ الأغشیة المخاطیة بالفم<br />&bull; شعور بحرارة شدیدة (ھبّات ساخنة)<br />&bull; انخفاض عدد الحیوانات المنویة (نقص الحیوانات المنویة)<br />&bull; أنیمیا (&quot;فقر الدم&quot;) (انخفاض في عدد خلایا الدم الحمراء)<br />&bull; شعور بوخز أو حرقان في موضع الحقن عقب تسرب الدواء خارج الورید. وقد یؤدي تسرب الدواء خارج الورید إلى الموت<br />الموضعي للأنسجة المحیطة بالأوردة، مما یتطلب تدخل جراحي<br />&bull; سمیة الكبد<br />&bull; ارتفاع إنزیمات الكبد بشكلِ مؤقت<br />&bull; وھن (فقدان أو نقص القوة الجسدیة، ضعف، وھن)<br />&bull; تحسس ضوئي (تحسس شدید للبشرة تجاه الشمس)<br />تأثیرات جانبیة أخرى: قد یتسبب دوكسوروبیسین محلول مُركز للتسریب الوَریدي في تغیر لون البول لمدة یوم أو یومین عقب أخذ<br />ا ولا یدعو للقلق. 􀌒 الدواء. ھذا الأمر طبیعی<br />الإبلاغ عن التأثیرات الجانبیة<br />إذا تعرضت للإصابة بأیة تأثیرات جانبیة، فیُرجي التحدث إلى طبیبك المعالج أو الصیدلي أو الممرض. ویشمل ذلك أیة تأثیرات<br />جانبیة مُحتمَلة غیر مُدرجة في ھذه النَّشرة. كما یمكنك أیضًا الإبلاغ عن التأثیرات الجانبیة بشكل مباشر إلى المركز الوطني للتیقظ<br />والسلامة الدوائیة (انظر القسم رقم ٦). عن طریق الإبلاغ عن التأثیرات الجانبیة، یُمكنك المساعدة في تقدیم المزید من المعلومات<br />حول أمان ھذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحفظ ھذا الدواء بعیدًا عن رؤیة ومتناول الأطفال.<br />یُحفظ في الثلاجة في درجة حرارة (من ۲ درجة مئویة إلى ۸ درجة مئویة). احفظ الزجاجة في العبوة الخارجیة بعیًدا عن الضوء.<br />یحظر استخدام ھذا الدَّواء بعد تاریخ انتھاء الصلاحیة المدون على العبوة. یُشیر تاریخ انتھاء الصلاحیة إلى الیوم الأخیر من ذلك<br />الشھر.<br />یحظر استخدام ھذا الدَّواء إذا لم یكن المحلول لونھ أحمر شفاف وخالي من الجزئیات العالقة.<br />مُعدّ للاستخدام لمرة واحدة فقط.<br />یجب التَّخلص من أي جزء غیر مستخدم من المنتج أو أیة مخلفات وفقًا للمتطلبات المحلیة.<br />یُرجى مراجعة التعلیمات الخاصة بالتعامل مع الأدویة السامة للخلایا.<br />٪ تحضیر محالیل للحقن بالتسریب داخل الورید. قد تم التحقق من وجود ثبات كیمیائي وفیزیائي عند استخدام كلورید الصودیوم ۰٫۹<br />محلول للحقن ودیكستروز ٥٪ محلول للحقن لمدة تصل إلى ۲۸ یومًا عند درجة حرارة تتراوح من ۲ إلى ۸ درجة مئویة ولمدة تصل<br />إلى ۷ أیام عند درجة حرارة ۲٥ درجة مئویة أثناء تحضیره بعیدًا عن الضوء في عبوة زجاجیة.<br />وفقًا لوجھة النظر المیكروبیولوجیة، یجب استخدام المنتج فورًا. فإذا لم یتم استخدامھ فورًا، تقع مسئولیة مدة وشروط حفظ الدواء قبل<br />الاستخدام على عاتق المستخدم، وعادةً لن تكون المدة أطول من ۲٤ ساعة عند درجة حرارة تتراوح من ۲ إلى ۸ درجة مئویة، ما لم<br />یكن قد تم تخفیف المستحضر في شروط تعقیم مضبطة ومعتمدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحتوي دوكسوروبیسین محلول مُركز للتسریب الوَریدي على المادة الفعّالة دوكسوروبیسین ھیدروكلورید.<br />تحتوي كل زجاجة بحجم ۱ مللیلتر على ۲ ملغم من دوكسوروبیسین ھیدروكلورید.<br />تحتوي كل زجاجة بحجم ٥ مللیلتر على ۱۰ ملغم من دوكسوروبیسین ھیدروكلورید.<br />تحتوي كل زجاجة بحجم ۱۰ مللیلتر على ۲۰ ملغم من دوكسوروبیسین ھیدروكلورید.<br />تحتوي كل زجاجة بحجم ۲٥ مللیلتر على ٥۰ ملغم من دوكسوروبیسین ھیدروكلورید.<br />تحتوي كل زجاجة بحجم ٥۰ مللیلتر على ۱۰۰ ملغم من دوكسوروبیسین ھیدروكلورید.<br />تحتوي كل زجاجة بحجم ۱۰۰ مللیلتر على ۲۰۰ ملغم من دوكسوروبیسین ھیدروكلورید.<br />تشتمل المكوّنات الأخرى على: كلورید الصودیوم وحمض الھیدروكلوریك (لضبط درجة الحموضة) وماء مٌعد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>دوكسوروبیسین محلول مُركز للتسریب الوَریدي ھو محلول شفاف، أحمر اللون خالِ من الجزیئات العالقة.<br />أحجام العبوة: ..<br />زجاجة واحدة بحجم ٥ مللیلتر ( ۱۰ ملغم/ ٥ مللیلتر).<br />زجاجة واحدة بحجم ۱۰ مللیلتر ( ۲۰ ملغم/ ۱۰ مللیلتر).<br />زجاجة واحدة بحجم ۲٥ مللیلتر ( ٥۰ ملغم/ ۲٥ مللیلتر)<br />زجاجة واحدة بحجم ٥۰ مللیلتر ( ۱۰۰ ملغم/ ٥۰ مللیلتر).<br />زجاجة واحدة بحجم ۱۰۰ مللیلتر ( ۲۰۰ ملغم/ ۱۰۰ مللیلتر).<br />قد لا یتم تسویق جمیع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك التصریح بالتسویق:<br />أكورد ھیلثكیر لیمتد<br />سیج ھاوس، ۳۱۹ طریق بینر، ھارو الشمالیة،<br />٤اتش اف، المملكة المتحدة. میدلسیكس اتش ایھ ۱<br />صنع لصالح أكورد ھیلثكیر لیمتد بواسطة:<br />إنتاس المحدودة للصناعات الدوائیة، أحمد أباد، ولایة جوجارات، الھند.<br />للحصول على أیّة معلومات بشأن ھذا الدواء، یُرجى الاتصال بالممثل المحلي لمالك التصریح بالتسویق:<br />المكتب العلمي لشركة أكورد ھیلثكیر، المملكة العربیة السعودیة<br />في شركة زمو التجاریة المحدودة<br />الریاض، العلیا، شارع العرفج، متفرع من شارع عبد الملك بن مروان،<br />خلف وزارة الداخلیة، مبنى أطلس، مكتب رقم ۱<br />+۹٦٦-۱۱-۲۱۷- ھاتف: ۰۱٤۰<br />mena-pv@accord-healthcare.com : البرید الإلكتروني<br />.(SA- ۰۳ )، إصدار رقم ( 02 / تمت الموافقة على ھذه النشرة ( ۲۰۲۰<br />للإبلاغ عن حدوث آثار جانبیة بالمملكة العربیة السعودیة، یُرجى الاتصال ب:<br />المركز الوطني للتیقّظ:<br />+۹٦٦-۱۱-۲۰٥- &bull; فاكس رقم: ۷٦٦۲<br />۲۳۱۷ - ۲۳٥٦ - ۹٦٦ + ، تحویلة: ۲۳٤۰ -۱۱-۲۰۳- &bull; المركز الوطني للتیقظ: ۸۲۲۲<br />&bull; مركز الاتصال بالھیئة العامة للغذاء والدواء بالسعودیة: ۱۹۹۹۹<br />npc.drug@sfda.gov.sa : &bull; البرید الإلكتروني<br />https://ade.sfda.gov.sa : &bull; الموقع الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            .(SA- ۰۳ )، إصدار رقم ( 02 / تمت الموافقة على ھذه النشرة ( ۲۰۲۰
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Doxorubicin 2mg/ml Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1ml contains 2mg Doxorubicin Hydrochloride
Each 5ml vial contains 10mg of Doxorubicin Hydrochloride.
Each 10ml vial contains 20mg of Doxorubicin Hydrochloride.
Each 25ml vial contains 50mg of Doxorubicin Hydrochloride.
Each 50ml vial contains 100mg of Doxorubicin Hydrochloride
Each 100ml vial contains 200mg of Doxorubicin Hydrochloride.
Excipient:
Contains sodium 3.5mg/ml (0.15mmol)
For full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion
The product is a clear, red solution, with a pH in the range of 2.5-3.5 and osmolality between 270mOsm/kg to 320mOsm/kg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin is indicated in the following neoplastic conditions,<br />Examples include:<br />&bull; Small cell lung cancer (SCLC)<br />&bull; Breast cancer<br />&bull; Advanced ovarian carcinoma<br />&bull; Intravesically for bladder cancer<br />&bull; Neoadjuvant and adjuvant therapy of osteosarcoma<br />&bull; Advanced soft tissue sarcoma in adults<br />&bull; Ewing&#39;s sarcoma<br />&bull; Hodgkin&#39;s disease<br />&bull; Non-Hodgkin&#39;s lymphoma<br />&bull; Acute lymphatic leukaemia<br />&bull; Acute myeloblastic leukaemia<br />&bull; Advanced multiple myeloma<br />&bull; Advanced or recurrent endometrial carcinoma<br />&bull; Wilms&#39; tumour<br />&bull; Advanced papillary/follicular thyroid cancer<br />&bull; Anaplastic thyroid cancer<br />&bull; Advanced neuroblastoma<br />Doxorubicin is frequently used in combination chemotherapy regimens with other cytotoxic drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin Injection should be administered only under the supervision of a qualified physician with extensive experience in cytotoxic treatment. Also, patients must be carefully and frequently monitored during the treatment (see section 4.4)<br />Due to the risk of often lethal cardiomyopathy, the risks and benefits of the individual patient should be weighted before each application.<br />Doxorubicin is administered intravenously and intravesically and must not be administered orally, subcutaneously, intramuscularly or intrathecally. Doxorubicin can be administered intravenously as bolus within minutes, as short infusion for up to an hour or as continuous infusion for up to 96 hours.<br />The solution is given via the tubing of a freely running intravenous infusion of sodium chloride 9mg/ml (0.9%) solution for injection or dextrose 50mg/ml (5%) solution for injection within 2 to 15 minutes. This technique minimizes the risk of thrombophlebitis or perivenous extravasation, which can lead to severe local cellulites, vesication and tissue necrosis. A direct intravenous injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration.</p><p>Intravenous administration<br />The dosage of Doxorubicin depends on dosage regimen, general status and previous treatment of the patient. Dose schedule of Doxorubicin Hydrochloride administration could vary according to indication (solid tumours or acute leukemia) and according to its use in the specific treatment regimen (as single agent or in combination with other cytotoxic agents or as a part of multidisciplinary procedures that include combination of chemotherapy, surgical procedure and radiotherapy and hormonal treatment).<br />Monotherapy<br />Dosage is usually calculated on the basis of body surface area (mg/m2). On this basis, a dose of 60-75mg/m2 body surface area is recommended every three weeks when Doxorubicin is used as a single agent.<br />Combination regimen<br />When Doxorubicin Hydrochloride is administered in combination with other antitumour agents with overlapping toxicity, such as high-dose i.v. Cyclophosphamide or related Anthracycline compounds such as Danuorubicin, Idarubicin and/or Epirubicin, the dosage of Doxorubicin should be reduced to 30-60mg/m2 every 3 &ndash; 4 weeks.<br />In patients, who cannot receive the full dose (e.g. in case of immunosuppression, old age), an alternative dosage is 15-20mg/m&sup2; body surface per week.</p><p>Intravesical administration:<br />Doxorubicin may be used by intravesical instillation for the treatment of superficial bladder carcinoma or in prophylaxis of tumour recurrence after transurethral resection (T.U.R) in patients with high risk of recurrence. The recommended Doxorubicin Hydrochloride dose for local intravesical treatment of superficial bladder tumours is instillation of 30-50mg in 25-50ml of sodium chloride 9mg/ml (0.9%) solution for injection. The optimal concentration is about 1mg/ml. Generally the solution should be retained intravesically for 1 to 2 hours. During this period the patient should be turned 90&deg; every 15 minutes. The patient should not drink fluids for 12 hours prior to the treatment to avoid undesired dilution with urine (this should reduce the production of urine to about 50ml/h). The instillation may be repeated with an interval of 1 week to 1 month, dependent on whether the treatment is therapeutic or prophylactic.</p><p>Patients with impaired hepatic function<br />Since Doxorubicin Hydrochloride is mainly excreted via liver and bile, the elimination of the medicinal product may be decreased in patients with hepatic function impairment or bile flow obstruction and this could result in severe secondary effects.<br />General dose adjustment recommendations in patients with hepatic function impairment are based on serum bilirubin concentration:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Serum Bilirubin </strong></p></td><td style="vertical-align:top"><p><strong>Recommended Dose </strong></p></td></tr><tr><td style="vertical-align:top"><p>20-50micro mole/L</p></td><td style="vertical-align:top"><p>&frac12; normal dose</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 50micro mol/L</p></td><td style="vertical-align:top"><p>&frac14; normal dose</p></td></tr></tbody></table><p>Doxorubicin is contraindicated in patients with severe liver function disorder (see section 4.3).</p><p>Patients with impaired renal function<br />In patients with renal insufficiency (GFR &lt; 10ml/min), only 75% of the planned dose should be given.<br />In order to avoid cardiomyopathy, it is recommended that the cumulative total lifetime dose of Doxorubicin (including related drugs such as Danuorubicin) should not exceed 450-550mg/m2 body surface area. If a patient with concomitant heart disease receives mediastinal and/or heart irradiation, prior treatment with alkylating agents, and high-risk patients (with arterial hypertension since &gt; 5 years, with prior coronary, valvular or myocardial heart damage, age over 70 years) with a maximum total dose of 400mg/m2 body surface area should not be exceeded and the cardiac function of these patients should be monitored (see section 4.4).</p><p>Dose in children<br />Dosage in children may need to be reduced, please refer to treatment protocols and the specialist literature.<br />Obese patients<br />A reduced starting dose or prolonged dose interval might need to be considered in obese patients (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance Doxorubicin Hydrochloride or to any of the excipients
Contraindications for intravenous administration
• Hypersensitivity to Anthracenediones or other Anthracyclines
• Marked persisting myelosuppression and/or severe stomatitis induced by previous treatment with other cytotoxic agents and/or radiation
• Previous treatment with maximum cumulative doses of Doxorubicin and/or other Anthracyclines (e.g. Danuorubicin, Epirubicin, Idarubicin) and Anthracenediones (see section 4.4).
• Generalized infection
• Severe impaired liver function
• Severe arrhythmias, heart failure, previous myocardial infarction, acute inflammatory heart disease
• Increased haemorrhagic tendency
• Breastfeeding (see section 4.6)
Contraindications for intravesical administration:
• Invasive tumours that have penetrated the bladder (beyond T1)
• Bladder inflammation
• Haematuria
• Difficult urinary catheter introduction (e.g. in large intravesical tumours)
• Breastfeeding (see section 4.6)
• Urinary tract infections
Doxorubicin may not be given during pregnancy and lactation (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin Injection should be administered only under the supervision of a qualified physician experienced in cytotoxic therapy for i.v. or intravesical use. Doxorubicin Hydrochloride may potentiate the toxicity of other anticancer therapies. A careful control of possible clinical complications should be performed, particularly in elderly patients, in patients with a history of heart disease, or with bone marrow suppression, or patients who previously have been treated with Anthracyclines, or treated with radiation in the mediastinum.<br />Initial treatment with Doxorubicin requires close observation of the patient and extensive laboratory monitoring. It could be recommended therefore, that patients be hospitalized at least during the first phase of treatment. Doxorubicin may cause infertility during the time of drug administration.<br />Patients should recover from the acute toxicities of prior cytotoxic treatment (such as stomatitis, neutropenia, thrombocytopenia, and generalized infections) before beginning treatment with Doxorubicin.</p><p>Before or during treatment with Doxorubicin the following monitoring examinations are recommended (how often these examinations are done will depend on the general condition, the dose and the concomitant medication):<br />&bull; radiographs of the lungs and chest and ECG<br />&bull; regular monitoring of heart function (LVEF by e.g. ECG, UCG and MUGA scan)<br />&bull; daily inspection of the oral cavity and pharynx for mucosal changes<br />&bull; blood tests: haematocrit, platelets, differential white cell count, SGPT, SGOT, LDH, Bilirubin, uric acid.<br />Treatment control<br />Prior to start of the treatment it is recommended to measure the liver function by using conventional tests such as AST, ALT, ALP and Bilirubin as well as the renal function, (see section 4.4).</p><p>Control of the left ventricular function<br />Analysis of LVEF using ultrasound or heart scintigraphy should be performed in order to optimize the heart condition of the patient. This control should be made prior to the start of the treatment and after each accumulated dose of approximately 100mg/m2 (see section 4.4).</p><p>Cardiac Function<br />Cardiotoxicity is a risk of Anthracycline treatment that may be manifested by early (i.e. acute) or late (i.e. delayed) events.<br />Early (i.e. Acute) Events: Early cardiotoxicity of Doxorubicin consists mainly of sinus tachycardia and/or ECG abnormalities such as non-specific ST-T wave changes. Tachyarrhythmias, including premature ventricular contractions and ventricular tachycardia, bradycardia, as well as atrioventricular and bundle-branch block have also been reported. These symptoms generally indicate acute transient toxicity. These effects do not usually predict subsequent development of delayed cardiotoxicity, and are generally not a consideration for discontinuation of Doxorubicin treatment. Flattening and widening of the QRS-complex beyond normal limits may indicate Doxorubicin Hydrochloride-induced cardiomyopathy. As a rule, in patients with a normal LVEF baseline value (=50%), a 10% decrease of absolute value or dropping below the 50% threshold indicates cardiac dysfunction and in such situation treatment with Doxorubicin Hydrochloride should be carefully considered.</p><p>Late (i.e. Delayed) Events: Delayed cardiotoxicity usually develops late in the course of therapy with Doxorubicin or within 2 to 3 months after treatment termination, but later events, several months to years after completion of treatment, have also been reported. Delayed cardiomyopathy is manifested by reduced left ventricular ejection fraction (LVEF) and/or signs and symptoms of congestive heart failure (CHF) such as dyspnoea, pulmonary oedema, dependent oedema, cardiomegaly and hepatomegaly, oliguria, ascites, pleural effusion and gallop rhythm. Subacute effects such as pericarditis/myocarditis have also been reported. Life threatening CHF is the most severe form of Anthracycline-induced cardiomyopathy and represents the cumulative dose-limiting toxicity of the drug.<br />Cardiac function should be assessed before patients undergo treatment with Doxorubicin and must be monitored throughout therapy to minimize the risk of incurring severe cardiac impairment. The risk may be decreased through regular monitoring of LVEF during the course of treatment with prompt discontinuation of Doxorubicin at the first sign of impaired function. The appropriate quantitative method for repeated assessment of cardiac function (evaluation of LVEF) includes multi-gated radionuclide angiography (MUGA) or echocardiography (ECHO). A baseline cardiac evaluation with an ECG and either a MUGA scan or an ECHO is recommended, especially in patients with risk factors for increased cardiotoxicity. Repeated MUGA or ECHO determinations of LVEF should be performed, particularly with higher, cumulative Anthracycline doses. The technique used for assessment should be consistent throughout follow up.<br />The probability of developing CHF, estimated around 1% to 2% at a cumulative dose of 300mg/m2 slowly increases up to the total cumulative dose of 450-550mg/m2. Thereafter, the risk of developing CHF increases steeply and it is recommended not to exceed a maximum cumulative dose of 550 mg/m2. If the patient has other potential risk factors of cardiotoxicity (history of cardiovascular disease, previous therapy with other Anthracyclines or Anthracenediones, prior or concomitant radiotherapy to the mediastinal/pericardial area, and concomitant use of medicinal products with the ability to suppress cardiac contractility, including Cyclophosphamide and 5-Fluoruracil), cardiotoxicity with Doxorubicin may occur at lower cumulative doses and cardiac function should be carefully monitored.</p><p>Children and adolescents are at an increased risk for developing delayed cardiotoxicity following Doxorubicin administration. Females may be at greater risk than males. Follow up cardiac evaluations are recommended periodically to monitor for this effect.<br />It is probable that the toxicity of Doxorubicin and other Anthracyclines or Anthracenediones is additive.</p><p>Liver function<br />The major route of elimination of Doxorubicin is the hepatobiliary system. Serum total bilirubin should be evaluated before and during treatment with Doxorubicin. Patients with elevated bilirubin may experience slower clearance of the drug with an increase in overall toxicity. Lower doses are recommended in these patients (see section 4.2). Patients with severe hepatic impairment should not receive Doxorubicin (see section 4.3).<br />Haematologic Toxicity<br />Doxorubicin may produce myelosuppression (See Section 4.8) haematologic profiles should be assessed before and during each cycle of therapy with Doxorubicin, including differential white blood cell (WBC) counts. A dose-dependent, reversible leucopenia and/or granulocytopenia (neutropenia) is the predominant manifestation of Doxorubicin haematologic toxicity and is the most common acute dose-limiting toxicity of this drug. Leucopenia and neutropenia generally reach the nadir between days 10 and 14 after drug administration; the WBC/neutrophil counts return to normal values in most cases by day 21. Dose reduction or increase of the dose interval should be considered if the blood values are not normalized. Thrombocytopenia and anaemia may also occur.</p><p>Clinical consequences of severe myelosuppression include fever, infections, sepsis/septicaemia, septic shock, haemorrhage, tissue hypoxia or death.<br />Secondary leukaemia<br />Secondary leukaemia with or without a preleukaemic phase, has been reported in patients treated with Anthracyclines (including Doxorubicin). Secondary leukaemia is more common when such medicinal products are given in combination with other DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic medicinal products or when doses of the Anthracyclines have been escalated. These leukaemias can have a 1 to 3 year latency period.<br />Intravesical administration<br />Intravesical administration of Doxorubicin may cause symptoms of chemical cystitis (i.e. dysuria, urinary frequency, nocturia, stranguria, haematuria, necrosis of the bladder wall). Special attention is needed in case of catheter problems (i.e. urethral obstruction caused by invasion of intravesical tumour). Intravesical administration is contraindicated for tumours that have penetrated the bladder (beyond T1).<br />Tile intravesical route of administration should not be attempted in patients with, invasive tumours that have penetrated the bladder wall, urinary tract infections, and inflammatory conditions of the bladder.<br />Control of serum uric acid<br />During therapy serum uric acid may increase. In case of hyperuricaemia antihyperuricaemic therapy should be initiated.<br />In patients with severely impaired renal function dose reductions may be necessary (see section 4.2).<br />Gastrointestinal effects<br />An antiemetic prophylaxis is recommended.<br />Note: Doxorubicin should not be used in the presence in inflammations, ulcerations or diarrhoea.</p><p>Extravasation<br />Perivenous misinjection results in local necrosis and thrombophlebitis. A burning sensation in the region of the infusion needle is indicative of perivenous administration. If extravasation occurs, the infusion or injection has to be stopped at once; the needle should be left in place for a short time and then be removed after short aspiration. In case of extravasation start intravenous infusion of Dexrazoxane, no later than 6 hours after extravasation (see the SmPC of Dexrazoxane for dosing and further information). In case Dexrazoxane is contraindicated, it is recommended to apply 99% Dimethylsulfoxide (DMSO) locally to an area twice the size of the area concerned (4 drops to 10cm&sup2; of skin surface area) and to repeat this three times a day for a period of no less than 14 days. If necessary, debridement should be considered. Because of the antagonistic mechanism, the area should be cooled after the application of DMSO (vasoconstriction vs. vasodilatation), e.g., to reduce pain. Do not use DMSO in patients who are receiving Dexrazoxane to treat Anthracycline-induced extravasation. Other measures have been treated controversially in the literature and have no definite value.<br />Radiotherapy<br />Radiation-induced toxicities (myocardium, mucosa, skin and liver) have also been reported. Special caution is mandatory for patients who have had radiotherapy previously, are having radiotherapy concurrently or are planning to have radiotherapy. These patients are at special risk of local reactions in the radiation field (recall phenomenon) if Doxorubicin Hydrochloride is used. Severe, sometimes fatal, hepatotoxicity (liver damage) has been reported in this connection. Prior radiation to the mediastinum increases the cardiotoxicity of Doxorubicin. The cumulative dose of 400mg/m&sup2;&nbsp;must not be exceeded especially in this case.</p><p>Infertility<br />Doxorubicin can have genotoxic effects. Doxorubicin may cause infertility during the time of drug administration. In women, Doxorubicin may cause amenorrhea. Although ovulation and menstruation appear to return after termination of therapy, premature menopause can occur. Women should not become pregnant during and up to 6 months after treatment.<br />Doxorubicin is mutagenic and can induce chromosomal damage in human spermatozoa. Oligospermia or azoospermia may be permanent; however, sperm counts have been reported to return to normospermic levels in some instances. This may occur several years after the end of therapy. Men undergoing Doxorubicin treatment should use effective contraceptive measures. Also are advised not to father a child during and up to 6 months after treatment and to seek advice on cryoconservation (or cryopreservation) of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with Doxorubicin.<br />Anticancer therapies<br />Doxorubicin may potentiate the toxicity of other anticancer therapies. Exacerbation of Cyclophosphamide-induced haemorrhagic cystitis and enhanced hepatotoxicity of 6-mercaptopurine have been reported, as with other cytotoxic agents, thrombophlebitis and thromboembolic phenomena including pulmonary embolism (in some cases fatal) have been coincidentally reported with the use of Doxorubicin (see section 4.8).<br />Vaccines<br />This medicinal product is generally not recommended in combination with live, attenuated vaccines. Contact to persons recently vaccinated against polio should be avoided. Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including Doxorubicin, may result in serious or fatal infections. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p><p>Tumour lysis syndrome<br />Doxorubicin may induce hyperuricaemia as a consequence of the extensive purine catabolism that accompanies drug-induced rapid lysis of neoplastic cells (tumour lysis syndrome) (see section 4.8). Blood uric acid levels, potassium, calcium phosphate and creatinine should be evaluated after initial treatment. Hydration, urine alkalinization, and prophylaxis with Allopurinol to prevent hyperuricaemia may minimize potential complications of tumour lysis syndrome.<br />A stinging or burning sensation at the site of administration may signify a small degree of extravasation. If extravasation is suspected or occurs, the injection should be discontinued and restarted in a different blood vessel. Cooling the area for 24 hours can reduce the discomfort. The patient should be carefully monitored for several weeks. Surgical measures might be necessary.<br />Doxorubicin Hydrochloride may impart a red colour to the urine. Patients should be cautioned that this does not pose any health hazards.<br />Dosage should not be repeated in the presence or development of bone marrow depression or buccal ulceration. The latter may be preceded by premonitory buccal burning sensations and repetition in the presence of this symptom is not advised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin cardiotoxicity is enhanced by previous or concurrent use of other Anthracyclines, or other potentially cardiotoxic drugs (e.g. 5-Fluorouracile, Cyclophosphamide or Paclitaxel) or with products affecting cardiac function (like calcium antagonists), When Doxorubicin is used together with the above mentioned agents, cardiac function must be followed carefully.<br />The use of Trastuzumab in combination with Anthracyclines (such as Doxorubicin) is associated with a high cardiotoxic risk. Trastuzumab and Anthracyclines should not be used in combination for the time being, except in well controlled clinical studies where the cardiac function is monitored. When Anthracyclines are used after the end of a therapy with Trastuzumab, an elevated risk of cardiotoxicity may result. The half-life of Trastuzumab is approximately 28.5 days and may persist in the circulation for up to 24 weeks.If possible, there should be a sufficiently long interval (up to 24 weeks) between the end of a therapy with Trastuzumab and the beginning of the Anthracycline therapy. Careful monitoring of the cardiac function is imperative.<br />Doxorubicin hepatotoxicity may be enhanced by other hepatotoxic treatment modalities (e.g. 6-Mercaptopurine).</p><p>Doxorubicin undergoes metabolism via Cytochrome P450 (CYP450) and is a substrate for the Pgp transporter, Concomitant administration of inhibitors of CYP450 and/or Pgp might lead to increased plasma concentrations of Doxorubicin and thereby increased toxicity. Conversely, concomitant administration of inducers of CYP450, such as Rifampicin and Barbiturates, might decrease plasma concentrations of Doxorubicin and reduce efficacy.<br />Ciclosporin, an inhibitor of CYP3A4 and Pgp, increased the AUC of Doxorubicin and Doxorubicinol by 55% and 350%, respectively. The combination might require dose adjustment. Cimetidine has also been shown to reduce the plasma clearance and increase the AUC of Doxorubicin.<br />Paclitaxel administered shortly before Doxorubicin may decrease clearance and increase plasma concentrations of Doxorubicin. Some data indicate that this interaction is less pronounced when Doxorubicin is administered before Paclitaxel.<br />Barbiturates may lead to an accelerated plasma clearance of Doxorubicin, while the concomitant administration of Phenytoin may result in lower plasma Phenytoin levels.<br />Elevated serum Doxorubicin concentrations were reported after the concomitant administration of Doxorubicin and Ritonavir.<br />The toxic effects of a Doxorubicin therapy may be increased in a combination with other cytostatics (e.g. Cytarabine, Cisplatin, and Cyclophosphamide). Necroses of the large intestine with massive haemorrhage and severe infections may occur in connection with combination therapies with Cytarabine.</p><p>Clozapine may increase the risk and severity of the heamatologic toxicity of Doxorubicin.<br />Marked nephrotoxicity of Amphotericin B can occur during Doxorubicin therapy.<br />As Doxorubicin is rapidly metabolized and predominantly eliminated by the biliary system, the concomitant administration of known hepatotoxic chemotherapeutic agents (e.g. Mercaptopurine, Methotrexate, Streptozocin) could potentially increase the toxicity of Doxorubicin as a result of reduced hepatic clearance of the drug. Dosing of Doxorubicin must be modified if concomitant therapy with hepatotoxic drugs is mandatory.<br />Doxorubicin is a potent, radio sensitizing agent (&ldquo;radio sensitizer&rdquo;), and recall phenomena induced by it may be life threatening. Any preceding, concomitant or subsequent radiation therapy may increase the cardiotoxicity or hepatotoxicity of Doxorubicin. This applies also to concomitant therapies with cardiotoxic or hepatotoxic drugs.<br />Doxorubicin may cause exacerbations of heamorrhagic cystitis caused by previous Cyclophosphamide therapy.<br />Doxorubicin therapy may lead to increased serum uric acid, therefore dose adjustment of uric acid lowering agents may be necessary.<br />Doxorubicin may reduce oral bioavailability of Digoxin.<br />During treatment with Doxorubicin patients should not be actively vaccinated and also avoid contact with recently polio vaccinated persons.</p><p>In a clinical study, an increase in Doxorubicin AUC of 21% was observed when given with Sorafenib 400mg twice daily. The clinical significance of this finding is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Doxorubicin has been found in foetal tissue (liver, kidney, lungs) at concentrations several times those in maternal plasma indicating that it does pass the placenta. In animals studies, Doxorubicin has shown embryo-, foeto- and teratogenic effects (see section 5.3) and also proved to be highly mutagenic in the Ames test.<br />Cytostatics should only be administered during pregnancy on strict indication, and the benefit to the mother weighed against possible hazards to the foetus.<br />Lactation<br />Doxorubicin has been reported to be excreted in human breast milk. A risk to the suckling child cannot be excluded. Since the use of Doxorubicin Hydrochloride during breastfeeding is contraindicated, breastfeeding should be discontinued during treatment with Doxorubicin (see section 4.3).<br />Fertility<br />For safety reasons, men wanting a baby should preserve unexposed sperm prior to treatment with Doxorubicin and abstain from engendering a child during and 6 months after therapy. Women with childbearing potential have to use effective contraception during Doxorubicin therapy and 6 months after treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the frequent occurrence of nausea and vomiting, driving cars and operation of machinery should be discouraged.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Doxorubicin often causes undesirable effects, and some of these effects are serious enough to entail careful monitoring of the patient. The frequency and kind of undesirable effects are influenced by the speed of administration and the dosage. Bone marrow suppression is an acute dose limiting adverse effect, but is mostly transient. Clinical consequences of Doxorubicin bone marrow/haematological toxicity may be fever, infections, sepsis/septicaemia, septic shock, haemorrhages, tissue hypoxia or death. Nausea and vomiting as well as alopecia are seen in almost all patients.<br />The following adverse events have been reported in association with Doxorubicin therapy:<br />Frequencies are defined using the following convention:<br />Very common (&ge;1/10)<br />Common (&ge;1/100 to &lt;1/10)<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Rare (&ge;1/10,000 to &lt;1/1,000)<br />Very rare (&lt;1/10,000), not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Common </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Uncommon </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Rare </strong></p></td><td style="vertical-align:top"><p><strong>Not known </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="3" style="vertical-align:top"><p>Sepsis, septicaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Neoplasms benign and malignant</p></td><td colspan="2" style="vertical-align:top"><p>Secondary acute myeloid leukaemia when in combination with antineoplastic drugs which damage the DNA. (see section 4.4), tumour lysis syndrome</p></td><td colspan="2" style="vertical-align:top"><p>Acute lymphocytic leukaemia and acute myelogenous leukaemia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders:</p></td><td colspan="2" style="vertical-align:top"><p>Bone marrow suppression, leucopenia and neutropenia</p></td><td colspan="2" style="vertical-align:top"><p>Thrombocytopenia, anaemia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune System disorders</p></td><td colspan="3" style="vertical-align:top"><p>Anaphylactic reactions</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td colspan="2" style="vertical-align:top"><p>Anorexia</p></td><td colspan="2" style="vertical-align:top"><p>dehydration</p></td><td style="vertical-align:top"><p>hyperuricaemia (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td colspan="2" style="vertical-align:top"><p>Conjunctivitis</p></td><td colspan="2" style="vertical-align:top"><p>keratitis and lacrimation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="2" style="vertical-align:top"><p>cardiomyopathy, (2%: e.g. decrease of LVEF. dyspnoea);</p></td><td colspan="2" style="vertical-align:top"><p>arrhythmia, asymptomatic reduction in left ventricular ejection fraction and congestive heart failure</p><p>Cardiotoxicity may be manifested in tachycardia including supraventricular tachycardia and ECG changes. (e.g. sinus tachycardia, tachyarrhythmia, ventricular tachycardia, bradycardia, atrio-ventricular and bundle branch block).</p><p>Routine ECG monitoring is recommended and caution should be exercised in patients with impaired cardiac function.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td colspan="2" style="vertical-align:top"><p>phlebitis</p></td><td colspan="2" style="vertical-align:top"><p>Thrombophlebitis; Thromboembolism; hot flushes, shock</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>nausea: vomiting; mucositis/stomatitis; diarrhoea,</p></td><td colspan="2" style="vertical-align:top"><p>Gastrointestinal haemorrhage, abdominal pain: ulceration of the mucous membranes in the mouth, pharynx , oesophagus and gastrointestinal tract may appear in combination with Cytarabine, ulceration and necrosis of the</p></td><td style="vertical-align:top"><p>Oesophagitis, gastric erosions, colitis hyperpigmentation of oral</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="8" style="vertical-align:top"><p>colon, in particular the caecum, have been reported (see section 4.5)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="4" style="vertical-align:top"><p>Bronchospasm, radiation pneumonitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorder&#39;s:</p></td><td colspan="2" style="vertical-align:top"><p>alopecia</p></td><td colspan="2" style="vertical-align:top"><p>Itching, local hypersensitivity reaction of the field of radiation (recall phenomenon)</p></td><td colspan="2" style="vertical-align:top"><p>urticaria, exanthema, local erythematous reactions along the vein which was used for the injection, hyperpigmentation of skin and nails, onycholysis</p></td><td style="vertical-align:top"><p>tissue hypoxia, acral erythema and plantar-palmar dysaesthesia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td colspan="4" style="vertical-align:top"><p>local reactions (chemical cystitis) might occur at intravesical treatment (i.e. dysuria, urinary frequency, nocturia, stranguria, haematuria, necrosis of the bladder wall)</p></td><td colspan="2" style="vertical-align:top"><p>acute renal failure,</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td colspan="4" style="vertical-align:top"><p>Amenorrhoea, oligospermia, azoospermia (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions:</p></td><td colspan="4" style="vertical-align:top"><p>anaphylactic reactions, shivering, fever, dizziness</p></td><td colspan="2" style="vertical-align:top"><p>A stinging or burning sensation at the administration site (see section 4.4) Malaise/weakness, asthenia, chills</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td colspan="4" style="vertical-align:top"><p>Hepatotoxicity, transient increase of liver enzymes,</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Surgical and medical procedure</p></td><td colspan="4" style="vertical-align:top"><p>Extravasation can lead to severe cellulitis, vesication and local tissue necrosis which may require surgical measures (including skin grafts) (see section 4.4)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of 250mg and 500mg of Doxorubicin have proved fatal.<br />Acute overdosage of Doxorubicin may lead to myelosuppression (particularly leucopenia and thrombocytopenia), generally 10 - 15 days following overdose, and acute cardiac alterations, which may occur within 24 hours. Treatment includes intravenous antibiotics, transfusion of granulocytes</p><p>and thrombocytes and reverse barrier nursing and treatment of heart effects. Moving the patient to a sterile room and the use of a haemopoietic growth factor should be considered.<br />Acute overdose with Doxorubicin will also result in gastrointestinal toxic effects (mainly mucositis). This generally appears early after drug administration, but most patients recover from this within three weeks.<br />Chronic overdosage, with a cumulative dose exceeding 550mg/m2 increases the risk for cardiomyopathy and may lead to heart failure.<br />Delayed cardiac failure may occur up to six months after the overdosage. Patients should be observed carefully and should signs of cardiac failure arise, be treated along conventional lines.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group<br />Anthracyclines and related substances ATC code: L01DB01<br />Doxorubicin is an Anthracycline antibiotic. The mechanism of action is not completely elucidated. It is postulated that Doxorubicin Hydrochloride exerts its antineoplastic effect via cytotoxic mechanisms of action especially intercalation into DNA, inhibition of the enzyme Topoisomerase II, and formation of reactive oxygen species (ROS). All of these have a deleterious effect on DNA synthesis: Intercalation of the Doxorubicin molecule leads to all inhibition of RNA and DNA polymerases by way of disturbances in base recognition and sequence specificity. The inhibition of Topoisomerase II produces single and double strand breaks of the DNA helix. Scission of DNA also originates from the chemical reaction with highly reactive oxygen species like the hydroxyl radical OH&bull;. Mutagenesis and chromosomal aberrations are the consequences.<br />The specificity of Doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastrointestinal tract and gonads are the main normal tissues damaged.<br />An important cause of treatment failure with Doxorubicin and other Anthracyclines is the development of resistance. In an attempt to overcome cellular resistance to Doxorubicin, the use of calcium antagonists such as Verapamil has been considered since the primary target is the cell membrane. Verapamil inhibits the slow channel of calcium transport and can enhance cellular uptake of Doxorubicin. A combination of Doxorubicin and Verapamil is associated with severe cardiotoxic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distribution<br />Following intravenous injection, Doxorubicin is rapidly cleared from the blood and widely distributed into tissues including lungs, liver, heart, spleen, lymph nodes, bone marrow and kidneys. The volume of distribution is about 25 litres. The degree of protein binding is 60-70%.<br />Doxorubicin does not cross the blood-brain barrier, although higher levels in liquor may be reached in the presence of brain metastases or leukemic cerebral dissemination. Doxorubicin is rapidly distributed into the ascites, where it reaches higher concentrations than in plasma. Doxorubicin is secreted into breast milk.<br />Elimination<br />The elimination of Doxorubicin from the blood is triphasic with mean half-lives of 12 minutes (distribution), 3.3 hours and about 30 hours. Doxorubicin undergoes rapid metabolism in the liver. The main metabolite is the pharmacologically active Doxorubicinol. Other metabolites are Deoxyrubicin Aglycone, Glucuronide and Sulphate conjugate. About 40 to 50% of a dose is excreted</p><p>in bile within 7 days, of which about half is excreted as unchanged drug and the rest as metabolites. Only 5-15% of the administered dose is eliminated in urine.<br />Special populations<br />As the elimination of Doxorubicin is mainly hepatic, impairment of liver function results in slower excretion, and consequently, increased retention and accumulation in plasma and tissues. Dose reduction is generally advised.<br />Although renal excretion is a minor elimination pathway for Doxorubicin, severe renal impairment might affect total elimination and require dose reduction.<br />In a study in obese patients (&gt;130% of ideal bodyweight) the Doxorubicin clearance was reduced and the half-life increased compared with a normal-weight control group. Dose adjustments might be necessary in the obese.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies from literature show that Doxorubicin affects the fertility, is embryo- and foetotoxic and teratogenic. Other data shows that Doxorubicin is mutagenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride<br />Hydrochloric acid (for pH adjustment)<br />Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin should not be mixed with Heparin, as a precipitate may form and it should not be mixed with 5-Fluorouracil as degradation may occur. Prolonged contact with any solution of an alkaline pH should be avoided, as it will result in hydrolysis of the drug.<br />Until detailed compatibility information about miscibility is available, Doxorubicin should not be mixed with other medicinal products than those mentioned under section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials
18 months
Opened vials
The product should be used immediately after opening the vial.
Prepared infusion solutions
Chemical and physical in-use stability has been demonstrated in 0.9% sodium chloride injection and 5% dextrose injection for up to 28 days at 2°– 8°C and for up to 7 days at 25°C when prepared in glass containers protected from light.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic condition.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.<br />Store in a refrigerator (2&deg;C - 8&deg;C).<br />Keep the vial in the outer carton in order to protect from light.<br />For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For 5ml,<br />Concentrate for solution for infusion is filled in 5ml Type - I clear tubular glass vial closed with chlorobutyl rubber stopper with teflon coating/ siliconised rubber stoppers and aluminium flip off pink seal.<br />For 10ml,<br />Concentrate for solution for infusion is filled in 10ml Type - I clear tubular glass vial closed with chlorobutyl rubber stopper with teflon coating/siliconised rubber stoppers and aluminium flip off pink seal.<br />For 25ml,<br />Concentrate for solution for infusion is filled in 30 ml Type - I clear molded glass vial closed with chlorobutyl rubber stopper with teflon coating/siliconised rubber stoppers and aluminium flip off pink seal.<br />For 50ml,<br />Concentrate for solution for infusion is filled in 50ml Type-I clear molded glass vial closed with chlorobutyl rubber stopper with teflon coating /siliconised rubber stopper and aluminium flip off pink seal.<br />For 100ml,<br />Concentrate for solution for infusion is filled in 100ml Type - I clear molded glass vial closed with chlorobutyl rubber stopper with teflon coating/siliconised rubber stoppers and aluminium flip off pink seal.<br />Pack sizes:<br />1 &times; 5ml vial<br />1 &times; 10ml vial<br />1 &times; 25ml vial<br />1 &times; 50ml vial<br />1 &times; 100ml vial<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin is a potent cytotoxic agent which should only be prescribed, prepared and administered by professionals who have been trained in the safe use of the preparation. The following guidelines should be followed when handling, preparing and disposing of Doxorubicin.<br />Preparation<br />1. Personnel should be trained in good technique for handling.<br />2. Pregnant staff should be excluded from working with this drug.</p><p>3. Personnel handling Doxorubicin should wear protective clothing: goggles, gowns, disposable gloves and masks.<br />4. All items used for administration or cleaning, including gloves, should be placed in high-risk waste disposal bags for high temperature (700&deg;C) incineration.<br />5. All cleaning materials should be disposed of as indicated previously.<br />6. Always wash hands after removing gloves.<br />Contamination<br />1. In case of contact with skin or mucous membrane, thoroughly wash the affected area with soap and water or sodium bicarbonate solution. However, do not graze the skin by using a scrubbing brush. A bland cream may be used to treat transient stinging of skin.<br />2. In case of contact with eye(s), hold back the eyelid(s) and flush the affected eyes with copious amounts of water for at least 15 minutes or normal sodium chloride 9mg/ml (0.9%) solution for injection. Then seek medical evaluation by a physician or eye specialist.<br />3. In the event of spillage or leakage treat with 1% sodium hypochlorite solution or most simply with phosphate buffer (pH&gt;8) until solution is destined. Use a cloth/sponge kept in the designate area. Rinse twice with water. Put all cloths into a plastic bag and seal for incineration.</p><p>Administration<br />Intravenous (IV) administration of Doxorubicin must be very careful and it is advisable to give the medicinal product via the tubing of a freely running intravenous sodium chloride 9mg/ml (0.9%) or dextrose 50mg/ml (5%) within 2 to 15 minutes. This method minimizes the risk of thrombosis development and perivenous extravasation that result in severe cellulitis, vesication and tissue necrosis, and also provides rinse of the vein after the administration.<br />Remnants of the medicinal product as well as all materials that have been used for dilution and administration must be destroyed according to hospital standard procedures applicable to cytotoxic agents with due regard to current laws related to the disposal of hazardous waste.<br />Disposal<br />Single use only. Any unused product or waste material should be disposed of in accordance with local requirements. Observe guidelines for handling cytotoxic drugs.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319 Pinner Road, North Harrow, Middlesex HA1 4HF, United Kingdom
Tel: +44 208 863 1427
Fax: +44 208 863 1426
E-mail: mena-info@accord-healthcare.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2014 (SA)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>